What Is Next-Generation Sequencing (NGS)?

Next-generation sequencing (NGS), also called massively parallel sequencing or high-throughput sequencing, is a DNA and RNA sequencing technology that determines the order of nucleotides in millions of DNA or RNA fragments at the same time, instead of one fragment per reaction as in Sanger sequencing.

Because each region is read many times over, NGS can sequence a targeted gene panel, a whole exome or a whole genome in one run, detect low-frequency variants, and cost far less per base than Sanger sequencing when samples are batched. In clinical laboratories, NGS is used for cancer profiling, inherited disease testing, infectious disease genomics, pharmacogenomics and noninvasive prenatal testing.

Last reviewed: November 19, 2026, by Sound Lab Consultants, an independent clinical laboratory consulting firm.

Gloved hand loading a clear sequencing flow cell into a benchtop next-generation sequencer beside a
Gloved hand loading a clear sequencing flow cell into a benchtop next-generation sequencer beside a

NGS vs Sanger sequencing

Sanger (capillary) sequencing reads one DNA fragment per reaction. NGS reads millions of fragments in parallel and uses bioinformatics to map the reads back to a reference genome (Behjati and Tarpey; NHGRI).

NGS vs Sanger sequencing at a glance

  • How it reads DNA. Sanger: One fragment per reaction, read by capillary electrophoresis. NGS: Millions of fragments read at the same time (massively parallel).

  • Scale. Sanger: A single gene or a few targets. NGS: A targeted panel, a whole exome or a whole genome in one run.

  • Depth. Sanger: Each position read once per reaction. NGS: Each position read many times (coverage depth), which supports detection of low-frequency and mosaic variants.

  • Variant types. Sanger: Substitutions and small insertions and deletions. NGS: Substitutions, indels, copy number changes and rearrangements from one data set.

  • Cost. Sanger: Low cost per reaction, high cost per base. NGS: Much lower cost per base when samples are batched; instruments, data storage and bioinformatics staff add cost.

  • Typical clinical role today. Sanger: Single-gene tests, known familial variants and orthogonal confirmation. NGS: Multigene panels, exome and genome testing, tumor profiling and pathogen genomics.

Sanger sequencing has not disappeared. Many clinical labs still use it for single-gene tests and to confirm selected NGS findings.

How NGS works: the four-stage workflow

  1. Nucleic acid extraction. DNA or RNA is isolated from blood, tissue (often formalin-fixed paraffin-embedded tissue), bone marrow, plasma cell-free DNA, swabs or cultured isolates, then checked for quantity and quality.

  2. Library preparation. The nucleic acid is broken into short fragments by mechanical or enzymatic methods, and sequencing adapters and sample-specific index barcodes are attached to each fragment. For targeted tests, the regions of interest are enriched by hybridization capture with probes or by multiplex PCR (amplicon) enrichment (Qin). See the NGS library preparation guide.

  3. Sequencing. The library is loaded onto a flow cell or a semiconductor chip, where fragments are clonally amplified and read in parallel. The most widely used short-read chemistry is sequencing by synthesis (SBS): a polymerase adds labeled nucleotides one base per cycle, and the instrument records which base was added to every cluster on the flow cell (NHGRI; Qin).

  4. Data analysis (bioinformatics). Software converts the signal into base calls with quality scores, removes low-quality reads, aligns reads to a reference genome, calls variants (SNVs, indels, copy number changes, fusions) and annotates them. A qualified professional then interprets the clinically relevant variants and the report is issued (Qin). See NGS bioinformatics pipeline validation.

Each stage has its own quality checks. The clinical NGS workflow compliance guide maps every step to CLIA and CAP expectations.

Short-read vs long-read sequencing

Short-read NGS produces reads of a few hundred bases; NHGRI describes a typical next-gen read as around 300 to 400 base pairs. Short reads are highly accurate and inexpensive at scale, and they are the most common choice for clinical panels, exomes and genomes.

Long-read sequencing reads single molecules thousands to hundreds of thousands of bases long. Long reads are easier to assemble and help resolve repeats, structural variants and other regions that short reads map poorly (NHGRI, Long-Read DNA Sequencing).

Labs choose between them, or combine them, based on the variant types the test must detect. Short-read data can miss repeat expansions and some regions with extreme GC content (Behjati and Tarpey).

Targeted panels, exome and genome sequencing

  • Targeted gene panel: a defined set of genes or hotspots, sequenced at high depth. The usual choice for tumor profiling and many inherited disease tests.

  • Whole exome sequencing (WES): the protein-coding regions of nearly all genes.

  • Whole genome sequencing (WGS): nearly all of the genome, coding and non-coding (MedlinePlus Genetics).

  • RNA sequencing: expression and fusion detection from RNA.

Clinical applications of NGS

  • Oncology. Tumor gene panels identify mutations, fusions and biomarkers that guide targeted therapy, and plasma cell-free DNA (liquid biopsy) testing can track circulating tumor DNA (Qin). Medicare covers NGS for patients with advanced cancer under defined conditions in NCD 90.2. See NGS and oncology LDTs.

  • Inherited (germline) disease. Multigene panels, exome and genome sequencing help diagnose rare and suspected genetic disorders (MedlinePlus Genetics; FDA germline NGS guidance).

  • Infectious disease. Pathogen sequencing identifies organisms and strains, detects antimicrobial resistance markers and traces outbreaks; CDC's Advanced Molecular Detection program uses next-generation and whole genome sequencing for public health (CDC AMD).

  • Pharmacogenomics. Pharmacogenomic panels genotype genes that affect drug metabolism and response. FDA keeps a table of pharmacogenomic biomarkers in drug labeling.

  • Noninvasive prenatal testing (NIPT). NIPT analyzes cell-free DNA fragments in a pregnant person's blood to screen for fetal chromosome conditions (MedlinePlus Genetics).

What a clinical lab needs to offer NGS testing

Running NGS for patient care is very different from running it in a research core. Before reporting results, a clinical lab needs:

  1. The right CLIA certificate. A CLIA certificate of compliance or certificate of accreditation covering high complexity testing in the relevant specialty (CMS CLIA). Many clinical NGS tests are laboratory developed tests (LDTs), and CMS treats every LDT as high complexity (CMS LDT and CLIA FAQs). See CLIA certificate types.

  2. Qualified personnel. A high complexity laboratory director, technical supervisor, clinical consultant, general supervisor and testing personnel under 42 CFR Part 493 Subpart M, plus staff with bioinformatics and variant interpretation expertise.

  3. Analytical validation. For a laboratory developed or modified NGS test, establish accuracy, precision, analytical sensitivity, analytical specificity, reportable range and any other needed characteristic before reporting patient results (42 CFR 493.1253(b)(2)). The AMP/CAP oncology guideline recommends an optimization phase first, reference materials, positive percentage agreement and positive predictive value by variant type, and minimum depth of coverage and sample numbers (AMP/CAP). See NGS assay validation under CLIA.

  4. Bioinformatics pipeline validation. Validate the pipeline end to end, lock software, reference genome and database versions, and revalidate after significant changes (AMP/CAP bioinformatics guideline).

  5. Wet lab and dry lab quality control. Wet lab QC covers nucleic acid and library quantity and quality, positive and negative controls and contamination control, with pre- and post-amplification separation (NGS lab design). Dry lab QC covers base quality scores, depth and uniformity of coverage, allele fraction, strand bias and GC bias (Gargis et al.). See NGS run QC metrics.

  6. Proficiency testing or alternative assessment. Enroll in PT where it exists, or run an alternative performance assessment at least twice a year. See NGS PT and the CAP checklist.

  7. Interpretation and reporting. Classify variants with the ACMG/AMP germline standard (ACMG/AMP) or the AMP/ASCO/CAP somatic standard (AMP/ASCO/CAP), and issue reports that meet 42 CFR 493.1291.

  8. Records and data retention. Keep validation records for as long as the test is in use and no less than 2 years, and keep QC and patient test records for at least 2 years (42 CFR 493.1105). Labs that are CAP-accredited also follow the CAP Molecular Pathology checklist; see the CAP NGS worksheets guide. New York specimens require NYS test approval (NYS CLEP LDT approval).

CDC's NGS Quality Initiative offers free quality management templates, including validation plans and sequencing QC SOPs, for labs whose NGS testing is subject to CLIA.

Is NGS regulated by the FDA?

Some NGS tests are FDA-authorized kits or systems, and a lab that runs one unmodified verifies it under 42 CFR 493.1253(b)(1). Many clinical NGS tests, however, are laboratory developed tests built and validated by the lab that runs them. FDA's 2024 LDT rule was vacated by a federal court on March 31, 2025, and FDA reverted its regulation in September 2025, so LDTs, including NGS LDTs, are overseen under CLIA, state law and, for accredited labs, accreditor standards. See What is a laboratory developed test? and FDA LDT rule status.

Frequently asked questions

What is next-generation sequencing (NGS)?

Next-generation sequencing (NGS) is a high-throughput DNA and RNA sequencing technology, also called massively parallel sequencing, that reads millions of DNA or RNA fragments at the same time. It can sequence a gene panel, an exome or a whole genome in a single run.

What does NGS stand for?

NGS stands for next-generation sequencing. Related terms are massively parallel sequencing, high-throughput sequencing and deep sequencing. Second-generation sequencing usually means short-read NGS, and third-generation sequencing usually means long-read, single-molecule sequencing.

How is NGS different from Sanger sequencing?

Sanger sequencing reads one DNA fragment per reaction and suits single genes or confirmation testing. NGS reads millions of fragments in parallel, reads each position many times and can detect many variant types across many genes at a much lower cost per base.

What are the main steps of NGS?

The four main steps are nucleic acid extraction, library preparation (fragmentation, adapter and index ligation and, for targeted tests, enrichment), sequencing on a flow cell or chip, and data analysis, which covers base calling, alignment, variant calling, annotation and interpretation.

What is sequencing by synthesis?

Sequencing by synthesis (SBS) is the most widely used short-read NGS chemistry. A polymerase adds labeled nucleotides to clonally amplified fragments on a flow cell one base per cycle, and the instrument records which base was added at every cluster.

What is the difference between short-read and long-read sequencing?

Short-read NGS produces highly accurate reads of a few hundred bases and is the most common choice for clinical testing. Long-read sequencing reads single molecules thousands to hundreds of thousands of bases long, which helps resolve repeats and structural variants.

What is NGS used for in medicine?

Clinical uses include tumor profiling and liquid biopsy in oncology, diagnosis of inherited and rare genetic disease, pathogen identification and outbreak tracing, pharmacogenomic testing and noninvasive prenatal testing from cell-free DNA.

Is clinical NGS testing high complexity under CLIA?

Usually. Many clinical NGS tests are laboratory developed tests, which CMS treats as high complexity, so the lab needs a high complexity CLIA certificate and qualified high complexity personnel.

How do you validate an NGS assay for clinical use?

Establish accuracy, precision, analytical sensitivity, analytical specificity and reportable range under 42 CFR 493.1253(b)(2) for each variant type and specimen type, validate the locked bioinformatics pipeline, and follow the AMP/CAP NGS validation guidelines before reporting patient results.

Does a clinical NGS test need FDA approval?

Not if it is a laboratory developed test. FDA's 2024 LDT rule was vacated in March 2025, so NGS LDTs are overseen under CLIA and state law. FDA-authorized NGS kits exist, and labs that use them unmodified verify them under CLIA.

Do I need a consultant to set up an NGS lab?

No. CLIA does not require one. Labs bring in an NGS consultant to plan space and workflow, choose a platform neutrally, design and document validation, set QC acceptance criteria and prepare for CLIA, CAP or New York State review.

Get help setting up or validating NGS

Sound Lab Consultants helps clinical laboratories plan, set up, validate and document NGS testing: lab layout, neutral platform selection, assay and bioinformatics validation, QC acceptance criteria and preparation for CLIA, CAP and New York State review.

Related guides

Sources

Sound Lab Consultants, 25 Arizona Pl, Chandler, AZ 85225. Independent consulting firm, not affiliated with, endorsed by or acting for NIH, NHGRI, CDC, CMS, FDA, the College of American Pathologists, AMP, ACMG, the New York State Department of Health, any sequencing platform maker or any accrediting organization. General educational and regulatory information, not medical or legal advice.